Engineering the Future of Kidney Recovery
Neukidney is developing therapeutic and regenerative platforms designed to improve outcomes for patients with chronic and acute kidney failure.
A targeted regenerative renal delivery platform designed to support future therapy delivery directly into kidney tissue.
Targeted cellular therapy delivery platform
Our innovative design is a biocompatible conduit implanted subcutaneously and into the kidney parenchyma to allow for steady infusion of cellular therapy into the kidney tissue.
Designed to support delivery directly into renal parenchyma.
Built around future stem-cell-based and regenerative therapy approaches.
Large-animal work supports intraparenchymal distribution of delivered cells.
Neukidney is positioned at the intersection of renal therapeutics, mitochondrial biology, NAD+ pathway optimization, and regenerative medicine.
QRX-3 is designed to enhance NAD+ availability, improve oxidative phosphorylation, reduce inflammatory cytokines, and reduce fibrosis-related tissue damage.
QRX-5 is being developed as a buffered NAD-focused therapy intended to accelerate renal recovery in hospitalized patients.
The regenerative catheter platform is designed to deliver stem-cell-based or regenerative therapies directly into renal parenchyma.
Neukidney's mission is to develop therapies that do more than slow kidney decline. The company is focused on therapies that may improve renal recovery, reduce dialysis dependency, decrease hospitalization burden, and improve quality of life for patients with kidney disease.
Develop therapies designed around renal recovery, not only disease slowing.
Target pathways that may delay or reduce progression to dialysis dependency.
Address chronic and acute kidney failure with a broader therapeutic platform.
Neukidney is advancing a development-stage renal biotechnology pipeline with potential milestones across clinical execution, CMC scale-up, regulatory alignment, and future strategic partnerships.
Neukidney is focused on therapies that may improve renal recovery, reduce dialysis dependency, decrease hospitalization burden, and improve quality of life for patients with kidney disease.
The company's development strategy combines NAD+ biology, mitochondrial support, renal recovery therapeutics, and catheter-enabled regenerative delivery.
Designed to improve mitochondrial energy transfer and support renal cellular recovery.
Programs are intended to reduce inflammatory cytokines and fibrosis-related tissue damage.
The catheter platform is designed to support direct renal parenchymal delivery of regenerative therapy.
Engineering the future of kidney recovery
Neukidney's leadership and advisory team is built to support the transition from clinical proof-of-concept to Phase 3 execution, manufacturing scale-up, and future regulatory submission.
Co-Founder of Neukidney, leading the company's vision to develop therapies that restore kidney function and reduce dialysis dependency. Dr. Ebima is a nephrologist in Pearland, Texas, specializing in kidney care and hypertension management.
Co-Founder of Neukidney, leading translational strategy and patient-centered development. A Fulbright scholar with experience leading healthcare implementation strategies for the Ministry of Health, New Zealand, and a Harvard Master's candidate.
Harvard alumni with a PhD and MBA degree. An industry expert with over 10 years management experience at Merck Pharmaceuticals, currently leading the global strategy division for Keytruda studies.
Advisor with deep expertise in renal therapeutics and clinical development strategy. President and co-founder of Trialteam.org, Harvard alumnus with 20+ years leading large clinical trials. Previously founded Hodges Clinical Group (acquired 2022).
Consultant with extensive experience serving as a liaison for companies navigating FDA approval processes. Currently serves as the FDA Liaison for the company, providing critical regulatory guidance and strategic direction.
Clear answers about Neukidney's investigational therapies, development stage, regulatory status, and partnership opportunities.
This section keeps the language careful, credible, and useful for investors, clinicians, research partners, and strategic collaborators.
Start a conversationQRX-3 is Neukidney's lead patented renal therapy for chronic kidney disease. It is designed as a multi-pathway NAD+ optimization therapy intended to support mitochondrial energy transfer, reduce inflammatory signaling, and protect kidney tissue.
QRX-5 is being developed as a buffered NAD-focused therapy for acute renal failure and acute tubular necrosis, with the goal of accelerating renal recovery in hospitalized patients.
The regenerative catheter platform is a patent-pending renal delivery approach designed to deliver regenerative therapy directly into renal parenchyma.
No. Neukidney's therapies and regenerative platform should be presented as investigational and subject to appropriate clinical, scientific, manufacturing, and regulatory review.
Neukidney is seeking strategic investors, board members, clinical development partners, and pharmaceutical collaborators to support Phase 3 execution, CMC scale-up, regulatory submission, and global commercialization.
You can contact Neukidney at info@neukidney.com or call 832-831-6135.
Neukidney is seeking strategic investors, board members, clinical development partners, and pharmaceutical collaborators to support Phase 3 execution, CMC scale-up, regulatory submission, and global commercialization.
